Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.

[1]  J. J. Wang,et al.  Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants , 2004, British Journal of Ophthalmology.

[2]  N. Ghazi,et al.  Impact of AREDS in a Developing Country 5 Years after Publication of the Study , 2011, European journal of ophthalmology.

[3]  S. McGhee,et al.  The incidental findings of age-related macular degeneration during diabetic retinopathy screening , 2014, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  P. Jong.  Prevalence of age-related macular degeneration in the United States. , 2004 .

[5]  Stephen W. Sorensen,et al.  Cost-effectiveness of vitamin therapy for age-related macular degeneration. , 2007, Ophthalmology.

[6]  Alan Cruess,et al.  An estimation of the worldwide economic and health burden of visual impairment , 2012, Global public health.

[7]  I. Zimmer-Galler,et al.  Feasibility of screening for high-risk age-related macular degeneration with an Internet-based automated fundus camera. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[8]  Jonathan Karnon,et al.  A Hybrid Cohort Individual Sampling Natural History Model of Age-Related Macular Degeneration: Assessing the Cost-Effectiveness of Screening Using Probabilistic Calibration , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  U Chakravarthy,et al.  A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. , 2008, Health technology assessment.

[10]  Hong Kong. Census.  Hong Kong life tables , 1973 .

[11]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[12]  R. Hayward,et al.  Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. , 2000, JAMA.

[13]  N. Bressler.  Age-related macular degeneration is the leading cause of blindness... , 2004, JAMA.

[14]  J. Sachs.  Macroeconomics and health: investing in health for economic development , 2002 .

[15]  Zachary Roth,et al.  Age-related macular degeneration: economic burden and value-based medicine analysis. , 2005, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[16]  S Prasad,et al.  National screening programme for diabetic retinopathy , 2001, BMJ : British Medical Journal.

[17]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[18]  Sharon D. Solomon,et al.  Vitamin usage patterns in the prevention of advanced age-related macular degeneration. , 2008, Ophthalmology.

[19]  A Hofman,et al.  Incidence and progression rates of age-related maculopathy: the Rotterdam Study. , 2001, Investigative ophthalmology & visual science.

[20]  Y. Kiyohara,et al.  Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. , 2009, Ophthalmology.

[21]  S. McGhee,et al.  Screening for diabetic retinopathy with or without a copayment in a randomized controlled trial: influence of the inverse care law. , 2013, Ophthalmology.